Operational Issues in Clinical Trial Disclosure of Global Trials

被引:0
|
作者
Shown M. Pelletier
Maureen A. Strange
Barbara J. Godlew
机构
[1] Business Operations,Clinical Trial Transparency, Global Development Medical Affairs
[2] Bristol-Myers Squibb,Medical Quality, Clinical Trial Registry, Global Medical Quality
[3] Eli Lilly and Company,undefined
[4] The FAIRE Company,undefined
[5] LLC,undefined
关键词
Maine; Clinical trial disclosure; FDAAA; Operations; Process;
D O I
暂无
中图分类号
学科分类号
摘要
In hospitals and clinics around the world, ordinary people place their health and their very lives in the hands of researchers who test new experimental drugs for safety and effectiveness. The public and legislators worldwide have expressed increasing interest in understanding how clinical trials are conducted and the results of those trials. The list of stakeholders has grown substantially in recent years to include medical and scientific academia, government agencies, regulatory authorities, and advocacy groups. Quite logically, stakeholders’ interests have shifted slightly from the registration of clinical trial protocol information to the posting of clinical trial results upon trial completion. Protocol registration and results reporting requirements are staggering, diverse, and complex. This article provides a look at industry experience with the operational challenges of clinical trial registries and results databases that the pharmaceutical, medical device, and biotechnology industry, and academia face when providing clinical trial information.
引用
收藏
页码:253 / 264
页数:11
相关论文
共 50 条
  • [21] Proposal for public disclosure about clinical trials
    Schwetz, BA
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (09): : 1146 - 1146
  • [22] New standard of disclosure set for clinical trials
    Kondro, W
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2004, 171 (08) : 839 - 839
  • [23] CLINICAL RESEARCH UNITS FOR THE TREATMENT OF PATIENTS WITH HIV DISEASE - OPERATIONAL ISSUES AND COMPONENTS NEEDED TO CONDUCT CLINICAL-TRIALS
    GODFREY, E
    STANLEY, K
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1993, 6 (06) : 567 - 574
  • [24] Choosing a Clinical Trial Disclosure System
    Tadikonda, Satish
    GENETIC ENGINEERING & BIOTECHNOLOGY NEWS, 2009, 29 (13): : 56 - 56
  • [25] CLINICAL TRIALS ON TRIAL
    不详
    LANCET, 1967, 2 (7515): : 553 - &
  • [26] Clinical trials on trial
    Obasogie, Osagie K.
    NEW SCIENTIST, 2011, 209 (2796) : 24 - 25
  • [27] Clinical trials on trial
    Vulto, Arnold G.
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY-SCIENCE AND PRACTICE, 2012, 19 (04): : 347 - 347
  • [28] Operational Experiences in China and Statistical Issues on the Conduct of Clinical Trials During the COVID-19 Pandemic
    Guo, Tong
    Chen, Chian
    Chiang, Chieh
    Chen, Chi-Tian
    Hsiao, Chin-Fu
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2020, 12 (04): : 438 - 442
  • [29] Issues in recruiting community-dwelling stroke survivors to clinical trials: The AMBULATE trial
    Lloyd, Gemma
    Dean, Catherine M.
    Ada, Louise
    CONTEMPORARY CLINICAL TRIALS, 2010, 31 (04) : 289 - 292
  • [30] The Global Kidney Patient Trials Network and the CAPTIVATE Platform Clinical Trial Design
    Kotwal, Sradha S.
    Perkovic, Vlado
    Jardine, Meg J.
    Kim, Dana
    Shah, Nasir A.
    Lin, Enmoore
    Coggan, Sarah
    Billot, Laurent
    Vart, Priya
    Wheeler, David C.
    de Boer, Ian H.
    Zhang, Hong
    Hou, Fan Fan
    Sugawara, Yuka
    Marion, Joseph
    Lewis, Roger J.
    Berry, Lindsay R.
    Mcglothlin, Anna
    Jha, Vivekanand
    De Nicola, Luca
    Gorriz, Jose L.
    Heerspink, Hiddo J. L.
    GKPTN Investigators
    CAPTIVATE Investigators
    JAMA NETWORK OPEN, 2024, 7 (12)